VivoSeq
Other

Colorectal Adenoma

11

Pipeline Programs↗

8

Active Trials↗

6

Companies Involved↗

Colorectal Adenoma is an emerging landscape with 11 programs across 6 companies. The most active players are Boehringer Ingelheim, Ferring, Merck & Co.. 2 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

22/100

Mech. Concentration

20/100

Completion Rate

80/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Ferring logo

Ferring

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 3Bayer logo

Bayer

1 program

Phase 3AbbVie logo

AbbVie

1 program

ApprovedTakeda logo

Takeda

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

14 of 15 classified programs — the dominant modality here.

7%ALL OTHERSPeptide17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 100% of 16 pipeline programs.

Analysis

Trial Status

19

clinical trials

Completed8 · 42%
Not yet recruiting4 · 21%
Active, not recruiting3 · 16%
Terminated2 · 11%
Recruiting1 · 5%
Unknown status1 · 5%

Clinical Trials

Trial Activity

19 trials

Multi-center Randomized Controlled Clinical Study of Shenling Baishu Granule to Prevent the Recurrence of Low-risk Colorectal Adenoma
Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT06930157·624 enrolled
Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome
Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02813824·852 enrolled
Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02965703·81 enrolled
Phase II Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Bioactivity in Patients With Sporadic Colorectal Adenomas and With Colorectal Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT03796884·150 enrolled
Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas
Not yet recruiting·JJiangsu Famous Medical Technology Co., Ltd.·N/A·NCT07129499·450 enrolled
The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma
Not yet recruiting·TThe Affiliated Hospital of Qingdao University·Phase 4·NCT07167342·300 enrolled
Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas
Not yet recruiting·JJiangsu Famous Medical Technology Co., Ltd.·N/A·NCT07123116·450 enrolled
Recurrence Mechanisms of Colorectal Adenoma After Resection and a Multi-Omics Research Protocol
Not yet recruiting·ZZhongshan Hospital Xiamen University·N/A·NCT07683312·30 enrolled
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI
Completed·National Cancer Institute (NCI)·Phase 2·NCT01312467·45 enrolled
Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence
Completed·SShanghai Jiao Tong University School of Medicine·Phase 2/3·NCT02226185·1,108 enrolled
Mesalazine Effects in Sporadic Colorectal Adenoma Patients
Completed·UUMC Utrecht·Phase 2·NCT01894685·74 enrolled
Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib
Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT00582660·40 enrolled
A Randomized Clinical Trial of Shenbai Granules in Reducing Recurrence of Colorectal Adenoma
Completed·JJiangsu Famous Medical Technology Co., Ltd.·Phase 2/3·NCT03616444·400 enrolled
Study of the MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Individuals With Advanced Colorectal Adenoma
Completed·—·Phase 2·NCT00773097·46 enrolled
A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00282386·2,586 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)